合并肥胖和糖尿病史独立关联银屑病生物制剂6个月疗效不佳
在Corrona银屑病注册研究中,2924例起始生物制剂治疗的患者中,合并肥胖使达到PASI75和PASI90的 odds 分别降低25%和30%,糖尿病史使PASI75降低31%、PASI90降低21%。肥胖与TNFi和IL-17i疗效降低相关,糖尿病独立于肥胖与IL-17i疗效不佳相关。高脂血症组无显著关联。
要点
- 肥胖和糖尿病史是生物制剂6个月疗效不佳的独立负性因素。
- 肥胖降低PASI75和PASI90达标 odds 分别达25%和30%。
- 糖尿病史降低PASI75和PASI90达标 odds 分别达31%和21%。
核心结论
- 合并肥胖和糖尿病史独立关联生物制剂治疗6个月时PASI75和PASI90应答率降低。
- 评估合并症负担有助于提高生物制剂治疗应答的可能性。
研究设计与样本
- 前瞻性分析Corrona银屑病注册研究中2924例起始生物制剂治疗且有基线和6个月随访的患者。
- 使用逻辑回归计算肥胖、糖尿病史、高血压和高脂血症与应答结局的调整OR和95%CI。
主要发现
- 肥胖降低PASI75达标 odds(OR 0.75,95%CI 0.64-0.88)和PASI90达标 odds(OR 0.70,95%CI 0.59-0.81)。
- 糖尿病史降低PASI75达标 odds(OR 0.69,95%CI 0.56-0.85)和PASI90达标 odds(OR 0.79,95%CI 0.63-0.98)。
- 肥胖与TNFi和IL-17i类别应答降低相关;糖尿病独立于肥胖与IL-17i治疗应答不佳相关,高血压与TNFi类别应答不佳相关性较弱。
- 高脂血症组未发现显著关联。
关键数值与推荐
- 肥胖者PASI75达标OR 0.75(95%CI 0.64-0.88),PASI90达标OR 0.70(95%CI 0.59-0.81)。
- 糖尿病史者PASI75达标OR 0.69(95%CI 0.56-0.85),PASI90达标OR 0.79(95%CI 0.63-0.98)。
临床怎么用
- 对银屑病患者起始生物制剂治疗前应评估肥胖和糖尿病等合并症负担。
- 合并肥胖或糖尿病史的患者可能需要更密切的疗效监测或考虑个体化治疗策略。
局限性
- 研究仅评估短期(6个月)有效性。
- 部分亚组样本量较小,限制了检测差异的统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Psoriasis is associated with comorbid systemic metabolic disease. OBJECTIVE: To assess possible associations of comorbid obesity, history of diabetes, hypertension, and hyperlipidemia with response to biologic treatment at 6 months among patients in CorEvitas' Psoriasis Registry. METHODS: Participants included 2924 patients initiating biologic therapy (tumour necrosis factor inhibitors [TNFi], interleukin [IL]-17i, IL-12/23i, or IL-23i) with baseline and 6-month follow-up visits available. Logistic regressions resulted in adjusted odd ratios (OR) and 95% confidence intervals (CI) for achievement of response in select outcomes for those with obesity and history of diabetes, hypertension, and hyperlipidemia relative to those without each. RESULTS: Overall, obesity reduced by 25% to 30% odds of achieving PASI75 (OR, 0.75; 95% CI, 0.64-0.88) and PASI90 (OR, 0.70; 95% CI, 0.59-0.81). History of diabetes reduced odds of achieving PASI75 by 31% (OR, 0.69; 95% CI, 0.56-0.85) and PASI90 by 21% (OR, 0.79; 95% CI, 0.63-0.98). Obesity was associated with lower response to TNFi and IL-17i classes. Independent of obesity, diabetes was associated with poorer outcomes when on IL-17i therapy and hypertension, to a lesser extent, when on the TNFi class. No significant associations were found in the hyperlipidemia group. LIMITATIONS: The study assessed only short-term effectiveness and small sample sizes limited the power to detect differences. CONCLUSION: Assessment of comorbid disease burden is important for improved likelihoods of achieving treatment response with biologics.
引用
- Enos CW, Ramos VL, McLean RR, et al. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry. J Am Acad Dermatol. 2021. PMID: 34256035. doi:10.1016/j.jaad.2021.06.883
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。